arGEN-X SE ADR (ARGX) News
Filter ARGX News Items
ARGX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ARGX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ARGX News From Around the Web
Below are the latest news stories about ARGENX SE that investors may wish to consider to help them evaluate ARGX as an investment opportunity.
argenx to Present at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A repl |
Exploring High Growth Tech Stocks for January 2025As we enter January 2025, global markets are navigating a landscape marked by fluctuating consumer confidence and mixed economic indicators, with major U.S. stock indexes experiencing moderate gains amidst a holiday-shortened trading week. In this environment, identifying high-growth tech stocks requires careful consideration of factors such as innovation potential and market adaptability, particularly as the technology-heavy Nasdaq Composite continues to show resilience despite recent... |
Argenx Secures Japanese Approval for VYVDURA in CIDP TreatmentArgenx Se ( (ARGX) ) has provided an update. Argenx SE announced that Japan’s Ministry of Health, Labour and Welfare has approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This approval marks the first time the neonatal Fc receptor blocker has been authorized for CIDP treatment, providing patients with a convenient at-home self-injection option. The approval is based on the results of the ADHERE trial, which demonstrated significant clinical improvements i |
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating PolyneuropathyVYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfolio approved in Japan for three indications – first country globally with access across three indications December 27, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Japan’s Ministry of |
Is Argenx SE (ARGX) the Best Performing Biotech Stock in 2024?We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at where Argenx SE (NASDAQ:ARGX) stands against the other biotech stocks. The Booming Biotechnology Sector The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and […] |
Here’s Why argenx SE (ARGX) Surged in Q3PGIM Jennison Health Sciences Fund recently released its third quarter 2024 investor letter. A copy of the letter can be downloaded here. Given concerns regarding the decreasing pace of U.S. employment and the associated concerns that U.S. interest rates may have been maintained at levels higher than necessary to moderate the pace of inflation, U.S. […] |
Should You Increase Your Holdings in argenx SE (ARGX)?TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” third-quarter investor letter. A copy of the letter can be downloaded here. Within equities, smaller or value-oriented stocks in developed economies yielded higher, whereas emerging markets saw the opposite trend. In the third quarter, the strategy returned 4.96% (gross) and […] |
Three Stocks Estimated To Be Undervalued In December 2024As global markets continue to reach record highs, driven by strong gains in major indices like the Dow Jones Industrial Average and S&P 500, investors are navigating a landscape influenced by geopolitical developments and domestic policy shifts. Amidst this environment, identifying undervalued stocks can offer potential opportunities for those looking to capitalize on discrepancies between market price and intrinsic value. |
Spotlight On High Growth Tech Stocks This December 2024As global markets continue to experience robust growth, with U.S. small-cap indices like the Russell 2000 reaching record highs, investor sentiment remains buoyed by domestic policy decisions and geopolitical developments. In this environment of heightened market activity and economic indicators showing mixed signals, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation capabilities and adaptability to shifting economic landscapes. |
Why Is Argenx SE (ARGX) Among the Best High Growth Healthcare Stocks to Invest In Now?We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a look at where Argenx SE (NASDAQ:ARGX) stands against the other high growth healthcare stocks. Global Healthcare Spending Trends and Investment Opportunities During lean economic times, investing in healthcare stocks is […] |